http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013158469-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 2012-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013158469-A |
| titleOfInvention | RETINOID LIPOSOMES TO STRENGTHEN HSP47 EXPRESSION MODULATION |
| abstract | 1. A pharmaceutical composition comprising a carrier for a medicament and a two-filament nucleic acid molecule, wherein the carrier for a medicament contains a specific amount of retinoid for stellate cells, and where the double-strand nucleic acid molecule contains the structure: 5 ′ (Ν) -Ζ 3 ′ (antisense strand ); 3 ′ Z ′ - (N ′) - z ′ ′ 5 ′ (semantic thread), where each N and N ′ represents a nucleotide that is unmodified or modified, or a non-standard component; where each (Ν) and (N ′) Represents oli a nucleotide in which each subsequent N or Ν ′ is connected to the next N or N ′ covalent bond; where each Ζ and Z ′ is independently present or absent, but if present, includes 1-5 consecutive nucleotides or non-nucleotide constituents, or a combination thereof, covalently attached to the 3′-end of the yarn in which it is present; where z ′ ′ may be present or absent, but if present, it is a capping group attached to the 5′-end (N ′); where each x and y independently represents an integer from 18 and 40; where the sequence (N ′) is complementary to the sequence (N); and where (N) includes the antisense sequence for the mRNA coding sequence for human hsp47, an example of which is SEQ ID NO: 1.2. The pharmaceutical composition of claim 1, wherein the siRNA contains oligonucleotide sequences selected from the group consisting of SEQ ID NOS: 60 and 127 (SERPINH1_2), SEQ ID NOS: 98 and 165 (SERPINH1_45a), and SEQ ID NOS: 101 and 168 (SERPINH1_51) .3. The pharmaceutical composition of claim 1, wherein the retinoid consists of a molecule selected from the group consisting of vitamin A, ret� |
| priorityDate | 2011-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.